Objectives: This study was conducted to examine the effects of hormone therapy on serum lipid levels in postmenopausal Korean women. Methods: This retrospective cohort study included 154 healthy postmenopausal Korean women. Seventy-nine women took oral estrogen (conjugated equine estrogen 0.625 mg/day or equivalent), and 75 applied estrogen transdermally using 0.1% 17ß-estradiol gel. Micronized progesterone (MP) was added to 40 women of oral group and 49 women in transdermal group. Serum levels of triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and lipoprotein (a) were measured before, 3 and 6 month after hormone therapy. Results: At baseline, mean body mass index (BMI) were lower (22.76 vs. 23.74 kg/m 2 ) and proportion of family history of cardiovascular disease (CVD) (61 vs. 39%) were higher in oral group. In oral group, LDL-C and lipoprotein(a) levels decreased, and triglyceride and HDL-C levels increased significantly after 3 and 6 months. There was no significant change in lipoprotein levels compared to the baseline in transdermal group. There were also no differences with additional MP. Changing pattern of HDL-C during 6 months was significantly different by the route of estrogen administration. 
Introduction
Cardiovascular disease (CVD) causes about one-third of all deaths for women worldwide, 1, 2 and develops about 7 to 10 years later in women than men on average. The number of cardiovascular deaths for women increases after menopause. 2, 3 Menopause accompanies unfavorable changes in serum lipoprotein concentrations because of a decrease in serum estrogen level. 4~7 Postmenopausal estrogen therapy has favorable effects on serum lipid, and has contributed to a decrease in the risk of CVD by 25% to 50% 8 and prevention of death by 50%. 8, 9 Serum levels of total cholesterol, lowdensity lipoprotein (LDL) and lipoprotein(a) were reduced, while serum levels of high-density lipoprotein (HDL) and triglyceride were increased after oral administration of estrogen. 10 On the contrary, serum levels of total cholesterol, LDL and lipoprotein(a) were reduced, while serum levels of 
Materials and Methods
This retrospective study included 154 healthy po- (Table 3) . No significant change was observed in estrogen alone and combined therapy groups ( Table 4 ).
Considering that combined use of MP did not influence the effect of estrogen on lipid profile based the above findings regardless of routes of hormone administration, a comparative analysis was performed by the route of estrogen administration by combining estrogen alone and combined estrogen-progesterone therapy groups. Although no difference was found in menopausal age between two groups, body mass index (BMI) was lower in oral administration group compared with transdermal administration group. In addition, a family history of CVD was more commonly noted in oral administration group (Table 5) . Table 6 shows the comparison of serum cholesterol levels in whole hormone therapy group by the route of estrogen.
A significant decrease was found in LDL and lipoprotein (a) levels and a significant increase was detected in triglyceride and HDL levels compared to the baseline levels in oral (Fig. 1) . Data are presented as mean ± standard deviation or number (%) *P < 0.05 indicates significant difference between two groups CVD: cardiovascular disease Data are presented as mean ± standard deviation or number (%) *P < 0.05 indicates significant difference within the group **P < 0.05 indicates significant difference between two groups ET: estrogen therapy, HDL: high-density lipoprotein, LDL: low-density lipoprotein, TD: Transdermal Even though the results of this study on the effects of oral administration are comparable to those of Western studies, a difference was found in the findings of previous studies that showed reduced LDL and elevated HDL levels after transdermal administration. This is thought to be attributable to racial differences in estrogen action. 22, 23 The administration of oral estrogens might be more beneficial than transdermal hormone therapy in terms of serum lipid profile in postmenopausal Korean women.
MP co-administered with estrogen had no significant influence on estrogenic activity. Unlike medroxyprogesterone acetate, the study results aligned with the outcomes of previous studies that a significant increase of serum HDL level was maintained. 15, 24 The combined use of MP is expected to be beneficial to endometrial protection in postmenopausal women with a uterus without attenuating the favorable effects of estrogen on serum lipid profile.
This study was meaningful in that it analyzed the effects on oral and transdermal hormone therapies on serum lipid profile in postmenopausal Korean women and the difference between with and without progesterone. This investigation was limited by the relatively small sample size as a retrospective study and a relatively short follow-up period of 6 months.
To sum up the above study result, hormone replacement therapy using oral estrogens clearly exerts favorable effects on lipoprotein metabolism in postmenopausal women.
Moreover, the addition of MP does not attenuate these favorable effects of estrogen on serum lipid metabolism. 
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